Valuation : Avacta Group Plc

Market Cap 319M 433M 373M 350M 600M 41.19B 604M 4.15B 1.61B 20.89B 1.63B 1.59B 69.15B P/E 2026 *
-9.75x
P/E 2027 * -10.1x
Enterprise Value 314M 425M 366M 344M 590M 40.47B 594M 4.07B 1.59B 20.52B 1.6B 1.56B 67.95B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Avacta Group Plc

1 day+2.49%
1 week+1.60%
Current month+5.11%
1 month+5.11%
3 months-5.54%
6 months+12.74%
Current year+20.52%
1 week 67
Extreme 67
74
1 month 63
Extreme 63
74.5
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
166.98
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 31/03/2024
Director of Finance/CFO 51 21/01/2025
Chief Tech/Sci/R&D Officer - 08/02/2026
Director TitleAgeSince
Director/Board Member 60 02/02/2020
Director/Board Member 71 16/08/2021
Director/Board Member 56 17/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/24 Sell

Chief Financial Officer

500,000 0.1393%
02/09/24 Free

Chief Executive Officer

3,600,000 1.0027%
02/09/24 Exercice

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
+1.40%+1.60%+14.97%-34.06% 433M
-1.66%-4.96%+49.84%+88.43% 68.13B
+0.53%+1.85%+45.30%+89.37% 63.6B
+1.31%+1.81%+37.52%+12.07% 25.57B
+2.77%-1.74%-16.16%+456.51% 26.6B
-0.46%-9.94%+0.98%-15.98% 25.52B
-9.71%-0.36%+245.87%+377.68% 18.23B
-0.68%-0.09%+28.62%-20.08% 19.69B
-1.49%-6.35%+0.78%+540.26% 15.16B
+0.35%+0.16%+46.96%+144.04% 13.54B
Average -0.66%-2.41%+45.47%+163.83% 27.65B
Weighted average by Cap. -0.69%-2.34%+45.32%+146.02%

Financials

2026 *2027 *
Net sales - -
Net income -33.4M -45.27M -38.97M -36.59M -62.75M -4.31B -63.2M -434M -169M -2.18B -170M -166M -7.23B -32.74M -44.36M -38.19M -35.86M -61.5M -4.22B -61.94M -425M -165M -2.14B -167M -163M -7.09B
Net Debt -5.58M -7.56M -6.51M -6.11M -10.48M -719M -10.55M -72.4M -28.17M -365M -28.38M -27.76M -1.21B 21.72M 29.43M 25.34M 23.79M 40.8M 2.8B 41.09M 282M 110M 1.42B 110M 108M 4.7B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
01/09/26 GBX 69.15 +1.40% 587,839
28/08/26 GBX 68.20 -1.16% 672,520
27/08/26 GBX 69.00 -0.29% 441,740
26/08/26 GBX 69.20 -0.43% 939,396
25/08/26 GBX 69.50 +1.02% 1,471,000
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6820GBP
Average target price
0.8167GBP
Spread / Average Target
+19.75%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVCT Stock